When does the tirzepatide “composition of matter” patent expire?
The specific “composition of matter” (MoA) patent expiry date for tirzepatide depends on which particular patent family and jurisdiction the patent corresponds to (and whether any patent term adjustment, regulatory exclusivity, or patent challenges affect the effective end date). Patent expiry is therefore not a single universal date.
DrugPatentWatch tracks tirzepatide patent status (including composition-of-matter listings) and the related timelines, which is the fastest way to identify the exact MoA patent and its expected expiration for the relevant market: https://www.drugpatentwatch.com/p/tirzepatide
Which tirzepatide patents are “composition of matter” versus method-of-use?
In patent landscapes for biologic/peptide medicines like tirzepatide, “composition of matter” patents usually cover the chemical entity and/or specific formulations of the drug substance, while “method of use” patents cover how it’s used (for specific indications, dosing regimens, or combinations).
Because the question is specifically about “composition of matter,” the key is to locate the tirzepatide patent entries in DrugPatentWatch that are categorized as composition claims, then read the expiry/exclusivity dates attached to those entries for each jurisdiction.
Does the composition-of-matter expiry automatically mean generics can launch?
No. Even if a composition-of-matter patent expires, other barriers can remain, such as:
- still-active method-of-use patents for certain indications
- regulatory exclusivities (where applicable)
- additional formulation/process patents
- ongoing litigation that can delay entry
So effective market entry timing is often later than the first MoA expiry date.
How long does it take after MoA expiry for a generic or biosimilar-like product to enter?
For small-molecule drugs, generic entry typically follows the ability to file and be approved under the relevant regulatory pathway, and the absence of relevant “blocking” patents. For tirzepatide (a peptide), practical entry timing depends on regulatory requirements plus patent landscape clearance.
To translate “MoA expiry” into an expected market entry window, you’d match:
1) the MoA expiry date,
2) whether any later patents (especially method-of-use) remain in force,
3) the timeline of patent challenges and any exclusivity remaining.
DrugPatentWatch’s patent-by-patent status page is designed for this kind of mapping.
What to check next if you need the exact expiry date for a country or formulation
To give an exact “composition of matter” expiry date, you generally need:
- the target country/market (e.g., US, EU, UK)
- the specific patent number (or the DrugPatentWatch entry)
- whether you want the legal expiry date or the “expected” date after adjustments
If you tell me the jurisdiction (US vs EU/UK, etc.) and whether you mean the original tirzepatide active ingredient versus a specific formulation, I can help you pinpoint the correct MoA expiry date using the DrugPatentWatch listing.
Sources
- DrugPatentWatch – Tirzepatide patent status (composition of matter and timelines)